Both DHT and enzalutamide had the anticipated impact on canonical AR genes (FKBP5 and NDRG1) in an androgen-sensitive prostate cancer cell line (Fig S2) and in differentiated hBECs (Fig 1D, Donor B1). Here, AR is linked to prostate cancer.